Archive for Ipamorelin

Ipamorelin and GHRP 6

Ipamorelin and GHRP 6

Ipamorelin is peptide that consists of five amino acids, thus enabling it to be considered a pentapeptide. It is occasionally referred to by the alternate names Ipamorelin Acetate, IPAM, and NNC-26-0161. It is considered to be a secretogogue peptide, meaning that it can play a role in energy homeostasis as well as the regulation and control of body weight in animal test subjects. It contains a molecular formula of C38H49N9O5, and a molecular mass of 711.85296.

Ipamorelin and GHRP – 6

Scientific study that has been based on animal test subjects has determined that there is a link between the functionality of Ipamorelin and the functionality of a similar peptide known as GHRP – 6. For example, it has been determined that both peptides have the capacity to stimulate the pituitary gland. This is the pea-sized gland located at the bottom of the hypothalamus at the base of the brain that is responsible for the regulation and control of an animal test subject’s endocrine system-related functions, ranging from growth and blood pressure to thyroid gland function and pain relief.

Additionally, both peptides have shown the capacity to block the production of somatostatin; a peptide that is primarily responsible for inhibiting the release of growth hormone, thus enabling an elevated level of secretion expression to occur within animal test subjects. Plus, both Ipamorelin and GHRP – 6 have been shown to stimulate the production of IGF-1. Also known as Insulin-Like Growth Factor 1 or somatomedin C, this peptide secreted by the liver and allows for an elevated functionality in terms of muscle and tissue growth and repair amongst animal test subjects.

The main difference between Ipamorelin and GHRP-6 can be found in the way the peptides work with ghrelin; the peptide that is produced by the stomach of animal test subjects as a means to stimulate the sensation of hunger. Whereas GHRP – 6 acts to boost the production of ghrelin, Ipamorelin does not work in such a manner. Instead, it functions to bind to major control points of gastric, appetite, and growth motility. The result of this is a more consistent level of homeostasis as it relates to hunger, especially in comparison to the after-effects of GHRP – 6’s presence.

What Can be Derived from Ipamorelin’s Presence

Because of the way in which Ipamorelin functions in conjunction with an animal test subject’s regulatory processes, scientific study has been able to hypothesize a host of various benefits that may be tied to the presence of the peptide. These theorized benefits include:
A rejuvenation of joints
An increase strength in joints
An increase strength in connective tissue
An increase in fat loss
An improved skin tone
An increase in bone mass

These various theoretical benefits have led a few scientific studies based on animal test subjects to determine that the peptide could have a potential link to the overall slowing down of the process of aging. The thought behind this theory is rooted in the way in which Ipamorelin can increase the secretions relating to growth while simultaneously suppressing the regulatory processes that would otherwise put a cap on an animal test subject’s ability to experience the kind of degradation that is typically associated with the aging process.

A Few Negative Side Effects

Scientific study based on animal test subjects has also derived a handful of negative side effects that could possibly be tied to the presence of Ipamorelin. These negative side effects primarily consist of headaches and head rushes (that is, a feeling of light-headedness). That being said, the research that has been conducted on animal test subjects has determined that these particular side effects tend to skew toward being mild in nature. Furthermore, it has also been determined that these negative side effects present themselves on a minimal scale.

Additionally, these studies show that the list of negative side effects that are tied to Ipamorelin are much shorter that the list of negative side effects that have been linked to the presence of GHRP – 6.

For Scientific Research Only

Despite the fact that there has been an extensive amount of research and study conducted in relation to Ipamorelin and its overall functionality, operational mechanics, theorized benefits, and negative side effects, it needs to be noted that all of the research that has been conducted and the subsequent results from such research has been exclusively built around the scientific study based on animal test subjects. The peptide is only intended for the use of scientific study at this point in time. As a result of this, any findings or observations that relate to Ipamorelin’s overall functionality, mechanics, theoretical benefits, or negative side effects should only be contained to the confines of a strictly controlled environment such as a laboratory or a medical research facility.

Share with your friendsEmail this to someoneTweet about this on TwitterShare on Google+Share on FacebookPin on PinterestDigg thisShare on StumbleUponShare on TumblrShare on Reddit



Ipamorelin is a growth hormone releasing peptide. It stimulates the body to release more human growth hormone and igf-1. Increases in gh and igf-1 can result in many benefits including:

- Builds Lean Tissue
- Lowers Body Fat
- Improved Recovery from training
- anti aging
- Improves Mood and Sleep Patterns

Ipamorelin is similar to other GHRP’s such as GHRP-2 and GHRP-6. However Ipamorelin does not cause sudden spikes in prolactin or cortisol like GHRP-2 and GHRP-6 can do. Both of those hormones when elevated can cause negative side effects. Cortisol is a steroid hormone that is released when stressed and can be very catabolic. Prolactin counteracts the effect of dopamine, which is responsible for sexual arousal. Elevated prolactin can cause a variety of unwanted physical and psychological effects.

Raun K et al. (1998) highlighted ipamorelin’s beneficial effects over the other ghrp’s. In pentobarbital anaesthetised rats, ipamorelin released GH with a potency and efficacy comparable to GHRP-6. In conscious swine, gh release after ipamorelin injection was high and again vey similar to GHRP6. In the same study GHRP-2 displayed higher potency but lower efficacy. The specificity for GH release was studied in swine. They found none of the GH secretagogues tested affected FSH, LH, PRL or TSH plasma levels. Administration of both GHRP-6 and GHRP-2 resulted in increased plasma levels of ACTH and cortisol. Very surprisingly, ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation. This lack of effect on ACTH and cortisol plasma levels was evident even when extremely high doses of were used. Ipamorelin was the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH.

A pharmacological profiling using GHRP and growth hormone-releasing hormone (GHRH) antagonists clearly demonstrated that ipamorelin, like GHRP-6, stimulates GH release via a GHRP-like receptor. However ipameolin is slow in its delivery unlike GHRP’s which spike GH levels at a faster rate. This another notable difference when researching ghrp’s. Moreover it has been shown that Ipamorelin is able to exert a dynamic control effect on the somatotroph population and on GH hormone content (Jiménez-Reina L et al. 2002).

A variety of promising effects have been displayed when ipamorelin has been studied. Adeghate E et al. (2004) examined the effect ipamorelin had on insulin secretion from pancreatic tissue fragments of normal and diabetic rats. Ipamorelin evoked significant (p<0.04) increases in insulin secretion from the pancreas of normal and diabetic rats. It was shown that ipamorelin stimulates insulin release through the calcium channel and the adrenergic receptor pathways.

Nitrogen balance is very important in humans. A positive value is often found during periods of growth, tissue repair or pregnancy. This means that the intake of nitrogen into the body is greater than the loss of nitrogen from the body, so there is an increase in the total body pool of protein. A negative value can be associated with burns, fevers, wasting diseases and other serious injuries and during periods of fasting. This means that the amount of nitrogen excreted from the body is greater than the amount of nitrogen ingested. Aagaard NK et al. (2009) studied the metabolic effects of Ipamorelin on selected hepatic measures of alpha-amino-nitrogen conversion during steroid-induced catabolism. Prednisolone was the steroid used to induce this catabolism. In prednisolone treated rats ipamorelin reduced CUNS by 20% (p<0.05), decreased the expression of urea cycle enzymes, neutralised N-balance, and normalized or improved organ N-contents. Therefore accelerated nitrogen wasting in the liver and other organs caused by prednisolone treatment was counteracted by treatment with Ipamorelin.

Ipamorelin is ideal for pre bed dosing

due to it’s long active life and minimal effect on hunger levels. When other GHRP’s are used such as GHRP 2/6 they can cause a sudden increase in appetite which can be awkward pre bed. Doses as little as 200mcg are highly effective but I feel Ipamorelin truly shines when you boom dose it. I have gone up to as much as 1mg pre bed and that was incredible. Although for most a dose of 500mcg would be more than enough when combined with a GHRH. My favourite peptide cycle to date has been CJC-1295 DAC with GHRP-2 through the day. Then a high dose of Ipam used pre bed.

Finally just want to list what I feel is a key advantage ipamorelin has over GH injections in a research environment. Unlike GH injections it does not shut down the body’s natural production of this hormone, it just enhances it. In the long run this is a huge factor and I feel future studies will highlight the importance of this in relation to health.


1. Aagaard NK, Gr&amp;oslash;fte T, Greisen J, Malml&amp;ouml;f K, Johansen PB, Gr&amp;oslash;nbaek H, &amp;Oslash;rskov H, Tygstrup N, Vilstrup H (2009) Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. PMID: 19231263 [PubMed - indexed for MEDLINE]
2. Adeghate E, Ponery AS (2004) Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. PMID: 15665799 [PubMed - indexed for MEDLINE]
3. Raun K, Hansen BS, Johansen NL, Th&amp;oslash;gersen H, Madsen K, Ankersen M, Andersen PH (1998) Ipamorelin, the first selective growth hormone secretagogue. PMID: 9849822 [PubMed - indexed for MEDLINE]
4. Jim&amp;eacute;nez-Reina L, Ca&amp;ntilde;ete R, de la Torre MJ, Bernal G (2002) Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. PMID: 12168778 [PubMed - indexed for MEDLINE]

Share with your friendsEmail this to someoneTweet about this on TwitterShare on Google+Share on FacebookPin on PinterestDigg thisShare on StumbleUponShare on TumblrShare on Reddit
eXTReMe Tracker